Production of the positron emitting radioisotope 86Y for nuclear medical application

Rösch, Frank; Qaim, S.M.; Stöcklin, G.

doi:10.1016/0969-8043(93)90131-s

Cited by 87 publications

(79 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sc process or through the 47 Ti(n, p) 47 Sc reaction. In both cases a highly enriched target is needed.…”

Section: Novel Low-energy β − Emittersmentioning

confidence: 99%

“…47 Sc, 67 Cu, 105 Rh, 161 Tb, 175 Yb and 186 Re, was started using a nuclear reactor, and in the case of 47 Sc, 105 Rh and 161 Tb it is still done at reactors, although following modified routes to achieve higher specific activity. The radionuclide 47 Sc is produced either via the 46 Ca(n, γ ) 47 Ca…”

Section: Novel Low-energy β − Emittersmentioning

confidence: 99%

“…Although the expected yield of 64 Cu via the latter reaction is higher, the availability of only lowenergy deuterons at medical cyclotrons has precluded the use of this reaction for production purposes. On the other hand, small amounts of 64 Cu have been produced using a deuteron induced reaction on 64 86 Y involve: (a) coprecipitation with La(OH) 3 followed by ion-exchange separation of radioyttrium from bulk lanthanum [47,48], (b) electrolysis [49][50][51], (c) multiple column chromatography [52], (d) solvent extraction [53] and (e) simple precipitation of the target element [54,55]. Out of those processes, the electrolytic method appears to be more promising.…”

Section: Novel Positron Emittersmentioning

confidence: 99%

“…They include low-energy β − emitters and α-particle emitters as well as Auger and conversion electron emitters. Among the β − emitters, the radionuclides 47 …”

Section: General Remarksmentioning

confidence: 99%

See 3 more Smart Citations

The present and future of medical radionuclide production

Qaim

2012

Radiochimica Acta

103

View full text Add to dashboard Cite

Reactor and cyclotron production of medical radionuclides / γ -ray emitters for SPECT / Positron emitters for PET / Corpuscular radiation emitters for internal radiotherapy / Low and intermediate energy nuclear reactions / Radionuclide generators / Future directionsSummary. Medical radionuclide production technology is well established. Both reactors and cyclotrons are utilized for production; the positron emitters, however, are produced exclusively using cyclotrons. A brief survey of the production methods of most commonly used diagnostic and therapeutic radionuclides is given. The emerging radionuclides are considered in more detail. They comprise novel positron emitters and therapeutic radionuclides emitting low-range electrons and α-particles. The possible alternative production routes of a few established radionuclides, like 68 Ga and 99m Tc, are discussed. The status of standardisation of production data of the commonly used as well as of some emerging radionuclides is briefly mentioned. Some notions on anticipated future trends in the production and application of radionuclides are considered.

show abstract

“…Sc process or through the 47 Ti(n, p) 47 Sc reaction. In both cases a highly enriched target is needed.…”

Section: Novel Low-energy β − Emittersmentioning

confidence: 99%

Section: Novel Low-energy β − Emittersmentioning

confidence: 99%

Section: Novel Positron Emittersmentioning

confidence: 99%

“…They include low-energy β − emitters and α-particle emitters as well as Auger and conversion electron emitters. Among the β − emitters, the radionuclides 47 …”

Section: General Remarksmentioning

confidence: 99%

See 2 more Smart Citations

The present and future of medical radionuclide production

Qaim

2012

Radiochimica Acta

103

View full text Add to dashboard Cite

show abstract

“…Radionuclide decay release positron particles which interact with the nearby negatively charged particle resulting in the emission of gamma rays which is detected by a PET or gamma camera to give an exact image of the target [5].…”

Section: Clinical Diagnosticmentioning

confidence: 99%

Radioisotopes and Their Biomedical Applications

Khan¹

2017

J Biomol Res Ther

View full text Add to dashboard Cite

Targeting peptides and positron emission tomography

Lundqvist

Tolmachev

2002

Biopolymers

View full text Add to dashboard Cite

Biologically active peptides have during the last decades made their way into conventional nuclear medicine diagnosis using single photon emission computed tomography (SPECT) and gamma-camera. Several clinical trails are also investigating the role of radiolabeled peptides for targeting radionuclide therapy. This has raised the question as to whether positron emission tomography (PET) can be used in order to obtain better quantitative information of the peptide distribution in tumor and healthy organs, i.e., to get a better dosimetry. Positron emitting analogs of the therapeutic radionuclides used have been produced and successfully applied in peptide pharmacokinetic measurements with PET. But the recent boom in (18)FDG-PET ((18)FDG = [(18)F]2-deoxy-2-fluoro-D-glucose), and with this a worldwide increasing number of PET systems, has also inspired several research groups to hunt for alternative labels to be used for peptide diagnostics and PET. The rapid kinetic of short peptides agrees well with the short half-lives of standard PET nuclides like (11)C and (18)F. Especially, (18)F appears to be excellent for labeling bioactive peptides due to its favorable physical and nuclear characteristics. However, with present techniques labeling peptides with (18)F is laborious and time-consuming, and is not yet a clinical alternative. Other halogens like (75, 76)Br and (124)I are, from the chemical point of view, easier to apply. But an even better labeling alternative may be positron emitting metal ions like (55)Co, (68)Ga, and (110m)In since they tend to give better intracellular retention and thus a better signal-to-background ratio than the halogen labels. The main drawback with these radionuclides is that they are not readily available. Some of these radionuclides also emit gamma in their decay that may affect the measuring properties of the PET equipment. This article reviews mainly the present situation of production and use of nonconventional positron emitters for peptide labeling.

show abstract

Production of the positron emitting radioisotope 86Y for nuclear medical application

Cited by 87 publications

References 4 publications

The present and future of medical radionuclide production

The present and future of medical radionuclide production

Radioisotopes and Their Biomedical Applications

Targeting peptides and positron emission tomography

Contact Info

Product

Resources

About